Polyclonal Antibody against Mouse FGF-21
SKU: 12180
PUBLICATIONS CITING THIS PRODUCT
- Kharitonenkov A, Shiyanova TL, et al. (2005) J Clin Invest; 115: 1627– 1635
- Badman MK, Pissios P, et al. (2007) Cell Metab; 5: 426– 437
- Nishimura T, Nakatake Y, et al. (2000) Biochim Biophys Acta; 1492: 203– 206
- Kurosu H, Choi M, et al. (2007) J Biol Chem; 282: 26687– 26695
- Kharitonenkov A, Shiyanova TL, et al. (2005) J. Clin. Invest. 115: 1627–35.
- Kharitonenkov A, Wroblewski VJ, et al. (2007) Endocrinology;148:774-81[7] Chavez AO, Molina-Carrion M, et al. (2009) Diabetes Care; 32:1542-6.
- Ye D, Li H, Wang Y, Jia W, Zhou J, Fan J, Man K, Lo C, Wong C, Wang Y, Lam KS. Circulating fibroblast growth factor 21 is a sensitive biomarker for severe ischemia/reperfusion injury in patients with liver transplantation. Scientific reports. 2016 Jan 25;6(1):1-9.
- Sun W, Nie T, Li K, Wu W, Long Q, Feng T, Mao L, Gao Y, Liu Q, Gao X, Ye D, Yan K, Gu P, Xu Y, Zhao X, Chen K, Loomes KM, Lin S, Wu D, Hui X. Hepatic CPT1A Facilitates Liver-Adipose Cross-Talk via Induction of FGF21 in Mice. Diabetes. 2021 Oct 21:db210363. doi: 10.2337/db21-0363. Epub ahead of print. Erratum in: Diabetes. 2022 Aug 1;71(8):1827.
- Arai K, Ono Y, Hirai N, Sugiura Y, Kaneko K, Matsuda S, Iio K, Kajino K, Saitoh T, Wei FY, Katagiri H, Inoue A. Chemogenetic activation of hepatic G12 signaling ameliorates hepatic steatosis and obesity. Biochim Biophys Acta Mol Basis Dis. 2024 Nov 12:167566.
$290.00Price